Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
0.961
-0.069 (-6.73%)
Nov 21, 2024, 11:49 AM EST - Market open
Lyell Immunopharma Employees
Lyell Immunopharma had 224 employees as of December 31, 2023. The number of employees decreased by 50 or -18.25% compared to the previous year.
Employees
224
Change (1Y)
-50
Growth (1Y)
-18.25%
Revenue / Employee
$281
Profits / Employee
-$910,665
Market Cap
268.25M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 224 | -50 | -18.25% |
| Dec 31, 2022 | 274 | 55 | 25.11% |
| Dec 31, 2021 | 219 | 29 | 15.26% |
| Dec 31, 2020 | 190 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cerus | 637 |
| uniQure | 480 |
| Lexicon Pharmaceuticals | 285 |
| Alpha Teknova | 211 |
| Absci | 155 |
| Sanara MedTech | 108 |
| ClearPoint Neuro | 107 |
| Aclaris Therapeutics | 91 |
LYEL News
- 16 days ago - Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 20 days ago - Lyell Immunopharma Completes Acquisition of ImmPACT Bio - GlobeNewsWire
- 27 days ago - Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth - Seeking Alpha
- 27 days ago - Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies - GlobeNewsWire
- 6 weeks ago - Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 2 months ago - Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Announces Participation in September Investor Conferences - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 - GlobeNewsWire